EDN1 and metastatic prostate carcinoma: In fact, the first clinical studies to specifically target osteoblasts in patients with metastatic prostate cancer was based on endothelin-1 (ET1), a mitogenic factor for osteoblasts that can promote the growth of osteoblasts at metastatic sites [7,8].